Evidence map›Paper›PMID 40401130›Full record

ReviewBiotechnologia2025

Second brain: reviewing the gut microbiome's role in lifestyle diseases.

Hindol Ray, Janatum Khatum, Srijan Haldar, Priyanka Bhowmik

Abstract readReview
In one paragraph

Review in Biotechnologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hindol RayDepartment of Biological Sciences, Adamas University, Kolkata, West Bengal, India.
Janatum KhatumDepartment of Biotechnology, Swami Vivekananda University, Barrackpore, West Bengal, India.
Srijan HaldarDepartment of Biotechnology, Swami Vivekananda University, Barrackpore, West Bengal, India.
Priyanka BhowmikDepartment of Biological Sciences, Adamas University, Kolkata, West Bengal, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent COVID-19 pandemic has highlighted another silent pandemic: lifestyle diseases. Conditions, such as cardiovascular diseases, anxiety, and type 2 diabetes (T2D), are increasingly becoming public health threats, affecting even younger populations worldwide. In recent years, extensive research has uncovered the pivotal role of the human gut microbiome in various aspects of human physiology, including metabolism, cellular homeostasis, immune defense, and disease development. The gut microbiome, often referred to as the "second brain," is now recognized as a key player in health and disease. Lifestyle factors such as diet, mental health, stress, exercise, and others significantly influence the composition of the gut microbiome. Imbalances in this composition, termed "dysbiosis," have been linked to a wide range of diseases, including cancer, cardiovascular diseases, obesity, T2D, asthma, and neurological disorders like Alzheimer's and Parkinson's disease. These findings underscore the profound influence of gut microbiome health on overall well-being. A working understanding of the gut microbiome's composition and its impact on disease processes is crucial for the advancement of personalized or precision medicine. This review article aims to explore recent advancements in the field, shedding light on how the gut microbiome contributes to the development and prognosis of lifestyle diseases.

Indexed as

Alzheimer’s diseasecancerdiabetesgut microbiomelifestyle diseasesobesity

Identifiers

PMID40401130
PMCPMC12089934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.